scholarly journals LB938 Efficacy of FMX101 4% topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Integrated summary from three phase 3 studies

2020 ◽  
Vol 140 (7) ◽  
pp. B9
Author(s):  
J. Del Rosso ◽  
L.F. Stein Gold ◽  
J. Weiss ◽  
L. Green ◽  
V. Stakias ◽  
...  
Keyword(s):  
Acne Vulgaris ◽  
Phase 3 ◽  
Severe Acne ◽  
Three Phase

Tazarotene 0.045% Lotion for Once-Daily Treatment of Moderate-to-Severe Acne Vulgaris: Results from Two Phase 3 Trials

2019 ◽  
Vol 19 (1) ◽  
pp. 70-77 ◽  
Author(s):  
Emil Tanghetti ◽  
William Werschler ◽  
Terry Lain ◽  
Eric Guenin ◽  
Gina Martin ◽  
...  
Keyword(s):  
Acne Vulgaris ◽  
Daily Treatment ◽  
Phase 3 ◽  
Two Phase ◽  
Once Daily ◽  
Severe Acne

scholarly journals Efficacy and safety of a novel topical minocycline foam for the treatment of moderate to severe acne vulgaris: A phase 3 study

2020 ◽  
Vol 82 (4) ◽  
pp. 832-837 ◽  
Author(s):  
Tooraj Joseph Raoof ◽  
Deirdre Hooper ◽  
Angela Moore ◽  
Martin Zaiac ◽  
Tory Sullivan ◽  
...  
Keyword(s):  
Acne Vulgaris ◽  
Efficacy And Safety ◽  
Phase 3 ◽  
Severe Acne

FMX101 4% Topical Minocycline Foam for the Treatment of Moderate-to-Severe Acne Vulgaris: Efficacy and Safety From a Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study

2018 ◽  
Vol 2 ◽  
pp. S56 ◽  
Author(s):  
Joseph Raoof ◽  
Deirdre Hooper ◽  
Angela Moore ◽  
Martin Zaiac ◽  
Tory Sullivan ◽  
...  
Keyword(s):  
Acne Vulgaris ◽  
Controlled Study ◽  
Efficacy And Safety ◽  
Phase 3 ◽  
Double Blind ◽  
Severe Acne

Abstract not available. Disclosures: Study sponsored by Foamix Pharmaceuticals.Copyright 2018 SKIN

scholarly journals Once-Daily Oral Sarecycline 1.5 mg/kg/day is Effective for Moderate to Severe Acne Vulgaris: Results from Two 12-Week, Phase 3, Randomized, Double-Blind Clinical Trials

2020 ◽  
Vol 4 (5) ◽  
pp. s52
Author(s):  
Angela Moore ◽  
Suzanne Bruce ◽  
Neil Sadick ◽  
Eduardo Tschen ◽  
Philip Werschler ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Acne Vulgaris ◽  
Phase 3 ◽  
Double Blind ◽  
Once Daily ◽  
Severe Acne

Abstract not available.

15202 A phase 3 study of 0.045% tazarotene lotion for once-daily treatment of moderate to severe acne vulgaris

2020 ◽  
Vol 83 (6) ◽  
pp. AB144
Author(s):  
Emil A. Tanghetti ◽  
Edward Lain ◽  
Lawrence J. Green ◽  
Gina Martin ◽  
Radhakrishnan (R.K.) Pillai ◽  
...  
Keyword(s):  
Acne Vulgaris ◽  
Daily Treatment ◽  
Phase 3 ◽  
Once Daily ◽  
Severe Acne

A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Results of 2 randomized, double-blind, phase 3 studies

2019 ◽  
Vol 80 (1) ◽  
pp. 168-177 ◽  
Author(s):  
Linda Stein Gold ◽  
Sunil Dhawan ◽  
Jonathan Weiss ◽  
Zoe Diana Draelos ◽  
Herman Ellman ◽  
...  
Keyword(s):  
Acne Vulgaris ◽  
Phase 3 ◽  
Double Blind ◽  
Severe Acne

The Efficacy and Safety of FMX101, Minocycline Foam 4%, for the Treatment of Acne Vulgaris: A Pooled Analysis of Phase 2 and Phase 3 Studies

2017 ◽  
Vol 1 ◽  
pp. s49
Author(s):  
Linda Stein Gold ◽  
Sunil Dhawan ◽  
Jonathan Weiss ◽  
Zoe D Draelos ◽  
Herman Ellman
Keyword(s):  
Acne Vulgaris ◽  
Pooled Analysis ◽  
Phase 2 ◽  
Efficacy And Safety ◽  
Phase 3

Abstract Not Available

Novel Polymeric Lotion Formulation of Once-Daily Tazarotene (0.045%) for Moderate-to-Severe Acne: Pooled Phase 3 Analysis

2020 ◽  
Vol 19 (3) ◽  
pp. 272-279
Author(s):  
Emil Tanghetti ◽  
William Werschler ◽  
Edward Lain ◽  
Eric Guenin ◽  
Susan Harris ◽  
...  
Keyword(s):  
Phase 3 ◽  
Once Daily ◽  
Severe Acne
Sign in / Sign up

Export Citation Format

Share Document